novocure(NVCR) - 2023 Q3 - Earnings Call Presentation
novocure(NVCR)2023-10-26 15:17patientforward HR, hazard ratio; ICI, immune checkpoint inhibitor; TTFields, Turnor Treating Fields; © 2023 Novocure GmbH phase 3 LUNAR trial met primary overall survival endpoint Overall survival (ITT population) 1.0 1.0 · 0.9 0.9 13.2 9.9 18.5 Median OS (months) MedianOS (months) 10.8 0.8 0.8 Log-rank P-value 0.035 0.03 Log-rank P-value HR (95% CI) HR (95% CI) 0.74 (0.56-0.98) 0.63 (0.41-0.96) 0.7 0.7 7% (2-15) 3-year survival (95% Cl) 18% (11-27) 3-year survival (95% Cl) 27% (15-42) 9% (3-21) bability of ...